CA
AST

Cliff Asness’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Cliff Asness’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-50,032
Closed -$194K – 2407
2015
Q3 		$194K Buy
+50,032
New +$230K ﹤0.01% 2068

Other funds holding AST

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cliff Asness's AST Position: Q4 2015 in Review

Cliff Asness sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2015, closing a stake of 50,032 shares — an estimated $194K sold.

Cliff Asness first reported a position in AST in Q3 2015 and held it in 1 quarter. The position peaked at $194K in Q3 2015. 56 funds tracked by Wall St. Rank hold AST as of Q4 2015.

  • Cliff Asness reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2015 after selling out during the quarter.
  • Cliff Asness sold 50,032 Asterias Biotherapeutics Inc. Series A shares in Q4 2015, an estimated $194K.
  • Cliff Asness first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 1 quarter.
  • Cliff Asness's Asterias Biotherapeutics Inc. Series A position peaked at $194K in Q3 2015.
  • 56 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2015.

Based on AQR Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.